Science and Research

Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (

BACKGROUND: PD-L1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic non-small cell lung cancer (NSCLC) in the clinical routine, but has limited value to distinguish responses. Assessment of KRAS and TP53 mutations (mut) as surrogate for an immunosupportive tumor microenvironment (TME) might help to close this gap. PATIENTS AND METHODS: 696 consecutive patients with PD-L1 high (

  • Bischoff, P.
  • Reck, M.
  • Overbeck, T.
  • Christopoulos, P.
  • Rittmeyer, A.
  • Lüders, H.
  • Kollmeier, J.
  • Kulhavy, J.
  • Kemper, M.
  • Reinmuth, N.
  • Röper, J.
  • Janning, M.
  • Sommer, L.
  • Aguinarte, L.
  • Koch, M.
  • Wiesweg, M.
  • Wesseler, C.
  • Waller, C. F.
  • Kauffmann-Guerrero, D.
  • Stenzinger, A.
  • Stephan-Falkenau, S.
  • Trautmann, M.
  • Lassmann, S.
  • Tiemann, M.
  • Klauschen, F.
  • Sebastian, M.
  • Griesinger, F.
  • Wolf, J.
  • Loges, S.
  • Frost, N.

Keywords

  • Kras
  • Nsclc
  • Tp53
  • checkpoint inhibitor
  • predictive biomarker
Publication details
DOI: 10.1016/j.jtho.2023.12.015
Journal: J Thorac Oncol
Work Type: Original
Location: Assoziierter Partner, ARCN, CPC-M, TLRC
Disease Area: LC
Partner / Member: ASK, BIH, DKFZ, Ghd, KUM, Thorax
Access-Number: 38096950

DZL Engagements

chevron-down